IJCS | Volume 32, Nº1, January/ February 2019

83 Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation. 2009;119(22):e561-87. 46. Anavekar NS, Chareonthaitawee P, Narula J, Gersh BJ. Revascularization in patients with severe left ventricular dysfunction: is the assessment of viability still viable? J Am Coll Cardiol. 2016;67(24):2874-87. 47. Beanlands R, Chow B, Dick A, Friedrich MG, Gulenchyn KY, Kiess M, et al;CanadianCardiovascularSociety;CanadianAssociationofRadiologists; CanadianAssociation of NuclearMedicine; CanadianNuclear Cardiology Society; Canadian Society of Cardiac Magnetic Resonance. CCS/CAR/ CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease – executive summary. Can J Cardiol. 2007;23(2):107-19. 48. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA Guideline for theManagement of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128(16):e240-327. 49. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, DicksteinK, et al; ESCCommittee for Practice Guidelines. ESCGuidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847. 50. Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, et al; Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006;22(1):23-45. Erratum in: Can J Cardiol. 2006;22(3):271. 51. Erthal F, ChowB, Heller G, Beanlands R. Nuclear Cardiology Procedures in the Evaluation of Myocadial Viability. In: Heller G, Hendel R. Nuclear cardiology: practical applications. 3rd ed. Philadelphia: Mc Graw Hill; 2017. chap. 21. 52. Mc Ardle BA, Beanlands RS. Myocardial viability: whom, what, why, which, and how? Can J Cardiol 2013;29(3):399-402. 53. Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernatingmyocardium in patients with postischaemic heart failure. Heart. 1998;79(3):281-8. 54. O’Meara E, Mielniczuk LM, Wells GA, deKemp RA, Klein R, Coyle D, et al; IMAGEHF investigators. Alternative ImagingModalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial. Trials. 2013 Jul 16;14:218. 55. de Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17(6):559-69. 56. Beaudoin J, Singh JP, Szymonifka J, Zhou Q, Levine RA, Januzzi JL, et al. Novel heart failure biomarkers predict improvement of mitral regurgitation in patients receiving cardiac resynchronization therapy- The BIOCRT Study. Can J Cardiol. 2016;32(12):1478-84. 57. Moe GW, Ezekowitz JA, O’Meara E, Lepage S, Howlett JG, Fremes S, et al; Canadian Cardiovascular Society. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015;31(1):3-16. Erratum in: Can J Cardiol. 2016;32(3):394. 58. Zelt JG, Liu PP, Erthal F, deKemp RA, Wells G, O'Meara E, et al. N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin T levels are related to the extent of hibernating myocardium in patients with ischemic heart failure. Can J Cardiol. 2017;33(11):1478-88. 59. Canty JM Jr, Suzuki G, Banas MD, Verheyen F, Borgers M, Fallavollita JA. Hibernating myocardium: chronically adapted to ischemia but vulnerable to sudden death. Circ Res. 2004;94(8):1142-9. 60. Luisi AJ Jr, Suzuki G, Dekemp R, Haka MS, Toorongian SA, Canty JM Jr, et al. Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med Off Publ Soc Nucl Med. 2005;46(8):1368-74. 61. Fallavollita JA, Heavey BM, Luisi AJ, Michalek SM, Baldwa S, Mashtare TL Jr, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63(2):141-9. 62. Higuchi T, Yousefi BH, Reder S, Beschorner M, Laitinen I, Yu M, et al. Myocardial kinetics of a novel [(18)F]-labeled sympathetic nerve PET tracer LMI1195 in the isolated perfused rabbit heart. JACC Cardiovasc Imaging. 2015;8(10):1229-31. 63. Sinusas AJ, Lazewatsky J, Brunetti J, Heller G, Srivastava A, Liu YH, et al. Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. J Nucl Med. 2014;55(9):1445-51. 64. Zelt JG, Renaud J, Mielniczuk L, Garrard L, Nalter O, Guo A, et al. Positron emission tomography provides accurate measure of cardiac sympathetic innervation compared to Carbon-11 hydroxyephedrine. [poster]. In: ACC. 18-Non invasive imaging [echocardiography, nuclear PET, MR and CT]. J Am Coll Cardiol. 2018;71(11):1482. 65. Canty JM Jr, Fallavollita JA. Hibernating myocardium. J Nucl Cardiol. 2005;12(1):104-19. 66. Camici PG, Dutka DP. Repetitive stunning, hibernation, and heart failure: contribution of PET to establishing a link. Am J Physiol Heart Circ Physiol. 2001;280(3):H929–36. 67. Abramson BL, Ruddy TD, deKemp RA, Laramee LA, Marquis JF, Beanlands RS. Stress perfusion/metabolism imaging: a pilot study for a potential new approach to the diagnosis of coronary disease in women. J Nucl Cardiol. 2000;7(3):205-12. 68. Abbott BG, Liu YH, Arrighi JA. [18F]Fluorodeoxyglucose as a memory marker of transient myocardial ischaemia. Nucl Med Commun. 2007;28(2):89-94. 69. Dou KF, Xie BQ, Gao XJ, Li Y, Yang YJ, He ZX, et al. Use of resting myocardial 18F-FDG imaging in the detection of unstable angina. Nucl Med Commun. 2015;36(10):999-1006. 70. AnselmDD, AnselmAH, Renaud J, Atkins HL, de Kemp R, Burwash IG, et al. Altered myocardial glucose utilization and the reverse mismatch pattern on rubidium-82 perfusion/F-18-FDG PET during the sub-acute phase following reperfusion of acute anterior myocardial infarction. J Nucl Cardiol. 2011;18(4):657-67. 71. Schwaiger M, Pirich C. Reverse flow-metabolism mismatch: what does it mean? J Nucl Med. 1999;40(9):1499-502. 72. Fukuoka Y, Nakano A, Tama N, Hasegawa K, Ikeda H, Morishita T, et al. Impairedmyocardial microcirculation in the flow-glucosemetabolism mismatch regions in revascularized acute myocardial infarction. J Nucl Cardiol. 2017;24(5):1641-50. 73. Wiefels C, Erthal F, de Kemp RA, et al. Radionuclide imaging in decision- making for coronary revascularization in stable ischemic heart disease. Curr Cardiovasc Imaging Rep. 2018. (in press). Erthal et al. Myocardial viability: from PARR-2 to IMAGE HF - current evidence and future directions Int J Cardiovasc Sci. 2019;32(1)70-83 Review Article This is an open-access article distributed under the terms of the Creative Commons Attribution License